在医学领域，特别是肿瘤治疗方面，CAR-T细胞疗法逐渐被越来越多的患者和医务工作者所关注。这种疗法通过改造患者的T细胞，使其能够识别和攻击癌细胞，展现出良好的治疗效果。然而，当人们思考CAR-T细胞疗法的潜力时，是否意识到关键的一点？如何准确评估CAR转染阳性率以及给药后T细胞的变化规律，成为了实现这一技术的重大挑战。 近日，北京百普赛斯生物科技股份有限公司申请了一项名为“Anti-CD19 CA ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

2 × 10 5 K562/CD19 cells were incubated for 1 h at 4 °C with the indicated concentration of His-tagged anti-CD19 scFvs for binding assays and with a mixture of 10 nm myc-tagged FMC63-scFv ...

为解决 CAR-T 细胞疗法成本高、生产受限等问题，研究人员开展了利用睡美人（SB）转座子工程化供体来源的抗 CD19.CD28.OX40.CD3ζ T 细胞（CAR CIK-CD19）治疗异基因造血干细胞移植（alloHSCT）后复发的 B 细胞前体急性淋巴细胞白血病（BCP-ALL）的研究。结果显示该疗法 ...

ALETA-001 comprises distinct binding domains: one from the CD19 protein that allows detection by any anti-CD19 CAR T cell; and an anti-CD20 antibody fragment. Together these domains comprise the ...

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Let's Talk Science. Let's Talk Medicine. The leading scientific social networking website and producer of educational virtual events and webinars.

Visit Exec Edge Research for Full Report By Exec Edge Research Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, ...

MT-601, Marker’s lead MAR-T cell therapy, is being evaluated in the nationwide multicenter Phase 1 APOLLO study ( clinicaltrials.gov identifier: NCT05798897) in patients with anti-CD19 CAR-T relapsed ...

“Our momentum continues in 2025, which marks a critical year of execution across our portfolio. Our cornerstone asset, budoprutug, a potentially best-in-class anti-CD19 monoclonal antibody, is being ...

Reports FY24 revenue $6.59M, consensus $8.32M. “In 2024, we made substantial progress advancing MT-601, our lead multi antigen recognizing-T ...

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24 th Annual Needham Healthcare ...